Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05271318

Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab and Pegylated Liposomal Doxorubicin as Treatment for Ovarian Cancer. — PROTA  

Platinum-resistant Ovarian Cancer Clinical Trial

Official title:
A Two-part, Phase I/Ib, Open-Label, Dose-escalation Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus (TILT-123) in Combination With Pembrolizumab (Phase I Part) and Pembrolizumab and Pegylated Liposomal Doxorubicin (Phase Ib Part) in Patients With Platinum Resistant or Refractory Ovarian Cancer.

Clinical Trial Summary

This is an open-label, phase 1, dose-escalation, multicenter and multinational trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with Pembrolizumab, or Pembrolizumab and Pegylated Liposomal Doxorubicin in patients with platinum resistant or refractory ovarian cancer.

Clinical Trial Description

This is an open-label, phase 1, dose-escalation, multicenter and multinational trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with Pembrolizumab, or Pembrolizumab and Pegylated Liposomal Doxorubicin in patients with platinum resistant or refractory ovarian cancer. TILT-123 is an oncolytic adenovirus coding for tumor necrosis factor alpha (TNFa) and interleukin 2 (IL-2). Pembrolizumab is a monoclonal antibody binding program cell death 1 (PD-1). Pegylated Liposomal Doxorubicin is a chemotherapy and a pegylated liposomal form of the anthracycline topoisomerase inhibitor, doxorubicin. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05271318
Study type Interventional
Source TILT Biotherapeutics Ltd.
Contact TILT Trials
Phone +358 509181 580
Email trials@tiltbio.com
Status Recruiting
Phase Phase 1
Start date May 17, 2022
Completion date January 2027
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05494580 - Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer Phase 1/Phase 2
Recruiting NCT05756907 - Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer Phase 1/Phase 2
Recruiting NCT04787289 - A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer Phase 2
Completed NCT04504916 - A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Solid Tumors (MK-2140-002) Phase 2
Recruiting NCT06090266 - A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Active, not recruiting NCT05979298 - Efficacy of Plasmid Elenagen in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Cancer Phase 2
Recruiting NCT04376073 - Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian Cancer Phase 2
Not yet recruiting NCT06321484 - Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer Phase 1
Terminated NCT02575807 - Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer Phase 1/Phase 2
Recruiting NCT06242470 - A Study of MGC026 in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT05310344 - Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer Phase 2
Withdrawn NCT05736952 - Oral Topotecan Combined With Anlotinib in Patients With Platinum-resistant Recurrent Ovarian Cancer Phase 2
Active, not recruiting NCT04374630 - Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian Phase 2
Recruiting NCT05551507 - IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer Phase 1/Phase 2
Active, not recruiting NCT03949283 - Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer Phase 3
Not yet recruiting NCT06315491 - A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer Phase 2
Recruiting NCT05870748 - REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 Phase 2/Phase 3
Recruiting NCT05198804 - A Study of ZN-c3 and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer Phase 1/Phase 2
Terminated NCT04718376 - A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer Phase 1
Recruiting NCT05081609 - A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or Chemotherapy or TransCon TLR7/8 Agonist in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies Phase 1/Phase 2